Drugs / Migaldendranib
Migaldendranib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07370155 | Jan → Aug 2026 overdue | — | Ashvattha Therapeutics, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05105607 | Jan → Aug 2022 | diabetic macular edema, wet macular degeneration | Ashvattha Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05387837 | Aug 2022 → May 2025 overdue | diabetic macular edema, wet macular degeneration | Ashvattha Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Migaldendranib | “Migaldendranib (MGB)” NCT07370155 ↗ |
| Known as | D-4517.2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05105607 ↗ |
| Known as | MGB | “Migaldendranib (MGB)” NCT07370155 ↗ |
| Action | Inhibit | “Hydroxyl Dendrimer VEGFR Tyrosine Kinase Inhibitor” NCT05105607 ↗ |
| Modality | Small molecule | — CHEMBL5314851 ↗ |
| Route | Subcutaneous | “Subcutaneous (SC) injection” NCT05105607 ↗ |